RESULTS	In a double-blind study , 628 patients with baseline LDL-C 145 to 250 mg/dL and triglycerides < or = 350 mg/dL were randomly assigned to receive 1 of the following for 12 weeks : ezetimibe ( 10 mg/d ) ; atorvastatin ( 10 , 20 , 40 , or 80 mg/d ) ; ezetimibe ( 10 mg ) plus atorvastatin ( 10 , 20 , 40 , or 80 mg/d ) ; or placebo .\